Compare Biogen Inc (BIIB) vs Tractor Supply Co (TSCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Tractor Supply Co — how do they compare? Biogen Inc trades at $191.09 (market cap $28.34B), while Tractor Supply Co trades at $31.18 (market cap $16.02B). The key difference: Biogen Inc is the larger of the two by market cap, and Tractor Supply Co pays a 3.14% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | TSCO | |
|---|---|---|
Market Cap | $28.34B | $16.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $62.65 |
52-Week Low | $122.68 | $29.14 |
Enterprise Value | $30.62B | $22.21B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Tractor Supply (TSCO) trades at $30.24, down 0.62% on the day, with a bearish technical signal and mixed earnings history. Recent quarters show two misses, but Q2 2026 expectations are set at $0.85 EPS. The company maintains stable revenue growth, reaching $15.52B in 2025, with a net income margin of 6.91% and a strong ROE of 45.5%. A recent partnership with Instacart aims to expand delivery services for rural customers.
The stock presents a value opportunity with a P/E of 14.9 below industry averages, supported by a 48% analyst buy rating and a $40 consensus price target implying significant upside. Risks include recent earnings volatility, consumer spending pressures, and competitive retail dynamics. The dividend yield of approximately 3.2% adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →
